Access Bio, Inc.

Equities

A950130

KR8840090003

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
7,180 ^KRW	-3.36%		+3.16%	-19.96%

2023	Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.	CI
2023	Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	CI

Access Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 15, 2023 at 07:35 am IST

Access Bio, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 155.11 million compared to KRW 185.95 million a year ago. Net income was KRW 41,175.3 million compared to KRW 282,404.81 million a year ago.

Basic earnings per share from continuing operations was KRW 1,212 compared to KRW 7,929 a year ago. Diluted earnings per share from continuing operations was KRW 1,123 compared to KRW 7,362 a year ago. Basic earnings per share was KRW 1,212 compared to KRW 7,929 a year ago.

Diluted earnings per share was KRW 1,123 compared to KRW 7,362 a year ago.

Latest news about Access Bio, Inc.

Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.	12/23/12	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	26/23/26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	26/23/26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	26/23/26	CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	26/23/26	CI
Access Bio, Inc. agreed to acquire Belight Investment for approximately KRW 130 billion.	26/23/26	CI
Access Bio, Inc's Equity Buyback announced on March 24, 2022, has expired with 1,840,483 shares, representing 5.22% for KRW 29,899.64 million.	23/23/23	CI
Access Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Access Bio, Inc.'s Equity Buyback Plan Extended till May 23, 2023.	22/23/22	CI
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency; BOS Up 2.6%	28/22/28	MT
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency	28/22/28	MT
AirBoss of America Brief: Defense Logistics Agency has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to US$410 Million to Access Bio	28/22/28	MT
AirBoss of America Brief: AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency	28/22/28	MT
QuidelOrtho, Orasure Technologies, Others Share $803 Million Contract From US Defense Logistics Agency	23/22/23	MT
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	27/22/27	CI
Wellysis announced that it has received KRW 5 billion in funding from Access Bio, Inc.	30/22/30	CI
Access Bio, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.	24/22/24	CI
Access Bio, Inc. authorizes a Buyback Plan.	24/22/24	CI
Access Bio, Inc. announced that it has received KRW 30 billion in funding from Meritz Securities Co., Ltd.	10/21/10	CI
Access Bio, Inc. announced that it expects to receive KRW 30 billion in funding from Meritz Securities Co., Ltd.	25/21/25	CI
Atomo Diagnostics Limited and Access Bio, Inc. Renegotiate Supply Agreements	05/21/05	CI
Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests	30/21/30	CI
Atomo Diagnostics Limited Receives FDA Clearance for Covid-19 Antibody Test	28/21/28	CI
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests	17/20/17	CI
Access Bio, Inc.'s CareStart™ COVID-19 Antigen Test Kit Using NanoAct™ Launched in the U.S	08/20/08	CI

Chart Access Bio, Inc.

Duration

Period

More charts

Company Profile

Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
ACCESS BIO, INC.	-19.96%	186M
BIOMÉRIEUX	-5.27%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.86%	8.07B
LANTHEUS HOLDINGS, INC.	+33.66%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.35%	4.21B
10X GENOMICS, INC.	-55.63%	2.99B
ANDON HEALTH CO., LTD.	+13.62%	2.73B
VITROLIFE AB	-3.65%	2.43B
MYRIAD GENETICS, INC.	+30.67%	2.29B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.31%	1.89B

Diagnostic & Testing Substances